-
公开(公告)号：US20210145880A1
公开(公告)日：2021-05-20
申请号：US17028701
申请日：2020-09-22
申请人： The Regents of the University of California , Seattle Children's Hospital DBA Seattle Children's Research Institute
发明人： Yvonne Y. CHEN , Eugenia ZAH , Michael C. JENSEN
IPC分类号： A61K35/17 , C07K16/46 , C12N5/0783 , C07K16/28 , C07K14/725 , C07K14/705
摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
公开(公告)号：US20210085719A1
公开(公告)日：2021-03-25
申请号：US17088005
申请日：2020-11-03
发明人： Michael C. Jensen
IPC分类号： A61K35/17 , A61P35/00 , C07K14/725 , C07K14/705 , C07K16/30
摘要： Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
-
公开(公告)号：US20210040448A1
公开(公告)日：2021-02-11
申请号：US16965964
申请日：2019-02-04
IPC分类号： C12N5/0783 , A61K35/17
摘要： Some embodiments provided herein relate to methods and compositions for making genetically modified T cells. In some such embodiments, CD4+ and CD8+ T cells are cultured in a single serum-free volume. In some embodiments, co-cultured CD4+ and CD8+ T cells can be transduced with a lentiviral vector, and a population of transduced T cells can be harvested within a shorter period of time than other conventional methods.
-
公开(公告)号：US20210002364A1
公开(公告)日：2021-01-07
申请号：US16794673
申请日：2020-02-19
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K16/28 , A61K35/17 , C12N5/0783 , C07K14/725 , C07K14/705 , C12N15/85 , A61K35/28 , A61K38/17 , C07K14/71 , C07K14/715 , C07K16/32 , A61K39/395 , C12N9/12
摘要： The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag, and wherein the polypeptide further comprises a flexible linker comprising amino acids GGGSGGGS (SEQ ID NO:45). Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
15.发明申请公开(公告)号：US20210000875A1
公开(公告)日：2021-01-07
申请号：US16979471
申请日：2019-03-12
IPC分类号： A61K35/17 , C07K16/28 , C07K14/705 , C07K14/725
摘要： Some embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to human extracellular domains of the IL-13 alpha 2 (IL13Ra2) receptor, cells containing such CARs, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors.
-
公开(公告)号：US20200325458A1
公开(公告)日：2020-10-15
申请号：US16605740
申请日：2018-04-19
发明人： David J. Rawlings , Karen Sommer , Swati Singh
摘要： Described herein are compositions and methods for treating, inhibiting or ameliorating X linked agammaglobulinemia (XLA) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate XLA. Exemplary embodiments include constructs and methods for gene therapy, which restore or increase BTK expression.
-
公开(公告)号：US20200215108A1
公开(公告)日：2020-07-09
申请号：US15750708
申请日：2016-08-03
发明人： Michael C. Jensen
IPC分类号： A61K35/17 , C07K16/30 , C07K14/725 , C07K14/705 , A61P35/00
摘要： Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
-
公开(公告)号：US20200087399A1
公开(公告)日：2020-03-19
申请号：US16480833
申请日：2018-02-06
发明人： Michael C. Jensen , James Matthaei
摘要： Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
-
公开(公告)号：US20190224237A1
公开(公告)日：2019-07-25
申请号：US16253572
申请日：2019-01-22
发明人： Michael C. Jensen , James Matthaei
IPC分类号： A61K35/17 , A61P35/00 , C12N5/0783 , C07K14/725
摘要： The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
公开(公告)号：US20170368098A1
公开(公告)日：2017-12-28
申请号：US15535972
申请日：2015-12-14
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
发明人： Yvonne Y. CHEN , Eugenia ZAH , Michael C. JENSEN
IPC分类号： A61K35/17 , C07K14/725 , C07K16/28 , C12N5/0783 , C07K16/46 , C07K14/705 , A61K39/00 , A61K38/00
CPC分类号： A61K35/17 , A61K38/00 , A61K2039/505 , C07K14/7051 , C07K14/70521 , C07K14/70596 , C07K16/2803 , C07K16/2887 , C07K16/46 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/40 , C12N5/0636 , C12N2510/00
摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
-
-
-
-
-
-
-
-
搜索结果
112 条记录 (耗时 0.04 秒)
